United States:
Supreme Court Denies Cert In Patent Eligibility Cases
15 January 2020
Foley & Lardner
To print this article, all you need is to be registered or login on Mondaq.com.
Voting after Friday’s conference, the Supreme Court
followed the Solicitor General’s advice and
denied certiorari in Hikma Pharmaceuticals USA Inc. v.
Vanda Pharmaceuticals Inc. (No. 18-817), but also denied cert. in
Athena Diagnostics, Inc. v. Mayo Collaborative
Services, LLC (No. 19-430), and HP Inc. v.
Berkheimer (No. 18-415).
Perhaps the Court has decided its work with 35 USC § 101 is
done, and the rest is up to Congress.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Are Your NDAs Up To Date?
Wolf, Greenfield & Sacks, P.C.
Nondisclosure agreements (NDAs) can be used to protect companies' confi dential and trade secret information. But you should resist the urge to have a vendor...
Legal Implications Of New York Times vs. OpenAI
BoyarMiller
The New York Times recently filed a landmark lawsuit against OpenAI and Microsoft, accusing them of copyright infringement in the training of the chatbot ChatGPT which launched just over a year ago.
